Oral THC Research Is Weighted Toward Capsules and Tablets, Not Every Kind of Edible

A 2020 systematic review found that capsules and tablets were the most commonly studied oral THC formulations. Its pharmacokinetic findings should not be presented as though brownies, oils, teas and pharmaceutical forms all have equally developed evidence.

The formulation was part of the review question

Twenty-six studies met the review's criteria. The evidence covered capsules, tablets, baked goods, oils and decoctions. These categories describe different preparations, and combining them under oral cannabis can obscure the uneven distribution of the research.

Absorption was variable and peaks delayed

The authors described substantial variability in oral THC absorption and later peak plasma concentrations than with other routes. They noted apparently greater variability in some baked-good and oil forms. Those observations do not supply one reliable onset or peak time for every oral product.

Exposure and effect need separate measurement

A plasma concentration curve characterizes exposure in the sampled compartment. It does not independently establish a person's symptom response or functional performance. A formulation-specific pharmacokinetic result therefore cannot become a universal prediction of intoxication duration.

Interpreting the evidence

When comparing oral THC studies, identify the formulation and what was actually measured. This review highlights an evidence imbalance and uncertainty. It does not provide a safe redosing interval, an exact edible-to-inhaled equivalence or a standardized effect timeline for an individual.

Related reading: interpreting cannabis tolerance claims.

Research reference

Lourdes Poyatos; Ana Pilar Pérez-Acevedo; Esther Papaseit; Clara Pérez-Mañá; Soraya Martin; Olga Hladun; Adrià Siles; Marta Torrens; Francesco Paolo Busardo; Magí Farré (2020). Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina. doi:10.3390/medicina56060309.

This discussion draws on the abstract and introductory material in the supplied research synthesis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us